SAN DIEGO, Dec. 05, 2016 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX), a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, announced today that management will present at the 9th Annual LD Micro Main Event Conference. The Presentation will take place on Tuesday, December 6, 2016 at 12:00PM PST, in Track 4 at the Luxe Sunset Hotel in Los Angeles, CA.
Management will be available on Tuesday, December 6 and Wednesday, December 7, 2016 for one-on-one meetings. To schedule a meeting or for more information, please contact [email protected].
About LD Micro
The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names. LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (LDMi) to exclusively provide intraday information on the entire sector.
About Cytori Therapeutics
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.
Cytori Therapeutics, Inc. Tiago Girao, +1 (858) 458.0900 [email protected]


Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Italy Fines Apple €98.6 Million Over App Store Dominance
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 



